The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

Gilead Sciences (GILD) reachead $85.83 at the closing of the latest trading day, reflecting a +0.91% change compared to its last close.

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Since the initial release of Open AI’s Chat GPT in 2022, the adoption of artificial intelligence (AI) technology has spread ...

Antiviral Drugs MarketThe antiviral drugs market is anticipated to experience significant growth, flourishing at an average ...

This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...